Literature DB >> 7810724

Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs.

M Naitoh1, H Suzuki, M Murakami, A Matsumoto, K Arakawa, A Ichihara, H Nakamoto, K Oka, Y Yamamura, T Saruta.   

Abstract

Rapid right ventricular pacing could induce congestive heart failure in conscious dogs with significant increase in plasma concentration of arginine vasopressin (AVP) (from 1.2 +/- 0.2 to 3.4 +/- 0.6 pg/ml). In this experimental model of heart failure, oral administration of the selective AVP V1 receptor antagonist OPC-21268 significantly increased cardiac output and improved renal function without significant changes in serum electrolytes and hormones. Oral administration of the selective AVP V2 receptor antagonist OPC-31260 induced marked water diuresis, which resulted in significant increases in serum sodium concentration, plasma renin activity, and plasma concentration of AVP, although it did not produce hemodynamic improvement. Combined administration of OPC-21268 and OPC-31260 showed supra-additive hemodynamic responses as well as additive renal and metabolic responses, i.e., it showed prolonged decrease in mean arterial pressure and profound increase in cardiac output. These results suggest that AVP plays a significant role in elevation of vascular tone through V1 receptors and plays a major role in retaining free water through V2 receptors in this model of heart failure. Furthermore, combined administration of V1 and V2 receptor antagonists could induce not only metabolic and hormonal responses but also more beneficial hemodynamic responses than those observed following treatment with V1 receptor antagonist alone.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7810724     DOI: 10.1152/ajpheart.1994.267.6.H2245

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  10 in total

1.  Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells.

Authors:  J Tsukada; A Tahara; Y Tomura; T Kusayama; N Ishii; T Yatsu; W Uchida; N Taniguchi; A Tanaka
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  Sex differences in vasopressin V₂ receptor expression and vasopressin-induced antidiuresis.

Authors:  Jun Liu; Nikhil Sharma; Wei Zheng; Hong Ji; Helen Tam; Xie Wu; Michaele B Manigrasso; Kathryn Sandberg; Joseph G Verbalis
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-01

3.  Upregulation of aquaporin-2 water channel expression in chronic heart failure rat.

Authors:  D L Xu; P Y Martin; M Ohara; J St John; T Pattison; X Meng; K Morris; J K Kim; R W Schrier
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

Review 4.  Vasopressin antagonists in heart failure.

Authors:  Ladan Golestaneh; Ashok Talreja; Thierry H Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2004-12

5.  Involvement of ERK and AKT signaling in the growth effect of arginine vasopressin on adult rat cardiac fibroblast and the modulation by simvastatin.

Authors:  Yan-Ping He; Lian-You Zhao; Qiang-Sun Zheng; Shao-Wei Liu; Xiao-Yan Zhao; Xiao-Long Lu; Xiao-Lin Niu; Xia Li
Journal:  Mol Cell Biochem       Date:  2008-06-26       Impact factor: 3.396

Review 6.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

7.  β-adrenergic receptor-mediated cardiac contractility is inhibited via vasopressin type 1A-receptor-dependent signaling.

Authors:  Douglas G Tilley; Weizhong Zhu; Valerie D Myers; Larry A Barr; Erhe Gao; Xue Li; Jianliang Song; Rhonda L Carter; Catherine A Makarewich; Daohai Yu; Constantine D Troupes; Laurel A Grisanti; Ryan C Coleman; Walter J Koch; Steven R Houser; Joseph Y Cheung; Arthur M Feldman
Journal:  Circulation       Date:  2014-09-09       Impact factor: 29.690

Review 8.  Treatment options for hyponatremia in heart failure.

Authors:  Steven R Goldsmith
Journal:  Heart Fail Rev       Date:  2008-09-06       Impact factor: 4.214

Review 9.  Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy.

Authors:  Zaid Abassi; Ilia Goltsman; Tony Karram; Joseph Winaver; Aaron Hoffman
Journal:  J Biomed Biotechnol       Date:  2011-01-11

10.  Conivaptan and its role in the treatment of hyponatremia.

Authors:  Jalal K Ghali; Jareer O Farah; Suleiman Daifallah; Hassan A Zabalawi; Hammam D Zmily
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.